Microparticle-associated vascular adhesion molecule-1 and tissue factor follow a circadian rhythm in healthy human subjects

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 909-915

  Madden, Leigh A ^a   Vince, Rebecca V ^a   Sandström, Marie E ^a   Taylor, Lee ^a   McNaughton, Lars ^a   Laden, Gerard ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Hull and East Riding Hospital   (United Kingdom)

Author keywords

Circadian rhythm; Microparticles; Tissue factor; Vascular cell adhesion molecule 1

Indexed keywords

THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIETARY INTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; MALE; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; VEIN PUNCTURE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL MEMBRANE STRUCTURES; CIRCADIAN RHYTHM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; REFERENCE VALUES; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 43949126859     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th08-01-0030     Document Type: Article

References (56)

1. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet II 1988; 349-360.
2. Bridges AB, Fisher TC, Scott N, et al. Circadian-rhythm of white blood-cell aggregation and free-radical status in healthy-volunteers. Free Radical Res Comm 1992; 16: 89-97.
3. Bridges AB, McLaren M, Saniabadi A, et al. Circadian variation of endothelial-cell function, red-blood-cell deformability and dehydro-thromboxane- b2 in healthy-volunteers. Blood Coag Fibrinol 1991; 2: 447-452.
4. Muller JE, Stone PH, Turi ZG, et al. circadian variation in the frequency of onset of acute myocardial-infarction. N Engl J Med 1985; 313: 1315-1322.
5. Ridker PM, Manson JE, Buring JE, et al. circadian variation of acute myocardial-infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82: 897-902.
6. Hjalmarson A, Gilpin EA, Nicod P, et al. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial-infarction. Circulation 1989; 80: 267-275.
7. Kapiotis S, Jilma B, Quehenberger P, et al. Morning hypercoagulability and hypofibrinolysis - Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19-21.
8. Kloner RA, Poole WK, Perritt RL. When through-out the year is coronary death most likely to occur? A 12-year population-based analysis of more than 220 000 cases. Circulation 1999; 100: 1630-1634.
9. Otto ME, Svatikova A, Barretto RBD, Santos S, Hoffmann M, Khandheria B, Somers V. Early morning attenuation of endothelial function in healthy humans. Circulation 2004: 2507-2510.
10. Ley K, Huo YQ. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001; 107: 1209-1210.
11. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM. Procoagulant microparticles - Disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
12. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
13. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
14. Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia 2002; 45: 550-555.
15. Pattanapanyasat K, Noulsri E, Fucharoen S, et al. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Clin Cytometry 2004; 57B: 23-31.
16. Horstman LL, Jy W, Jimenez JJ, et al. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135.
17. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial microparticles (EMP) as vascular disease markers. Adv Clin Chem 2005; 39: 131-157.
18. Osterud B, Bjorklid E. Blood borne tissue factor (including microparticles). In: ten Cate H, Levi M, eds. Molecular mechanisms of disseminated intravascular coagulation: Eurekah.com; 2003.
19. Semeraro N, Colucci M. Endothelial cell pertubation and disseminated intravascular coagulation. In: ten Cate H, Levi M, eds. Molecular mechanisms of disseminated intravascular coagulation: Eurekah.com; 2003.
20. Banner DW, Darcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
21. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human-tissues - implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097.
22. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99: 3962-3970.
23. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902.
24. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2007.
25. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
26. Nieuwland R, Berckmans RJ, RotteveelEijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-3541.
27. del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
28. Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96: 1233-1239.
29. Jafri SM, Vanrollins M, Ozawa T, et al. Circadian Variation in platelet-function in healthy-volunteers. Am J Cardiol 1992; 69: 951-954.
30. Soulban G, Labrecque G, Barbeau G. Time-dependent variations in the coagulation-factor-II, coagulation-factor-VII, coagulation-factor-IX, and coagulation-factor-X in young and elderly volunteers. Chronobiol Int 1995; 12: 206-213.
31. Pinotti M, Bertolucci C, Portaluppi F, et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005; 25: 646-649.
32. Elherik K, Khan F, McLaren M, et al. Circadian variation in vascular tone and endothelial cell function in normal males. Clin Sci 2002; 102: 547-552.
33. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haem 2004; 2: 1118-1126.
34. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211-217.
35. Millarcraig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 1: 795-797.
36. Maple C, Kirk G, McLaren M, et al. A circadian variation exists for soluble levels of intercellular adhesion molecule-1 and E-selectin in healthy volunteers. Clin Sci 1998; 94: 537-540.
37. Mosevold KA, Bruserud O. Circadian variations do not have a major impact on serum levels of soluble (s) L-selectin (CD63L), s-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals. Scand J Clin Lab Invest 2002; 62: 75-79.
38. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases - The atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219-4225.
39. Menown IBA, Mathew TP, Gracey HM, et al. Prediction of recurrent events by D-dimer and inflammatory markers in patients with normal cardiac troponin I (PREDICT) study. Am Heart J 2003; 145: 986-992.
40. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-825.
41. Stenvinkel P, Lindholm B, Heimburger M, et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association,vith malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Trans 2000; 15: 1624-1630.
42. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
43. Distler JHW, Huber LC, Hueber AJ, Reich CF, Gay S, Distler O, Pisetsky DS. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis 2005; 10: 731-741.
44. Jy WC, Mao WW, Horstman LL, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Molecules Dis 1995; 21: 217-231.
45. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. Cardiology 2000; 93: 7-10.
46. Jy W, Hortsman LL, Jiminez JJ, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1842-1843.
47. Biro E, Nieuwland R, Sturk A. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1843-1844.
48. Dignat-George F, Sabatier F, Camoin-Jau L, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1844-1845.
49. Hugel B, Zobari F, Freyssinet J-M. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1846-1847.
50. Nomura S. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1847-1848.
51. Shet AS, Key NS, Hebbel RP. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1848-1850.
52. Jiminez JJ, Jy W, Hortsman LL, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1850-1851.
53. Shah MD, Bergeron A, Dong J, et al. Measuring microparticles: Pitfalls and modifications. J Thromb Haemost 2007; 5 (Suppl 2): P-M-443.
54. Shermata WA, Jy W, Delgado S, et al. Interferon-β1a reduces plasma CD31+ endothelial microparticles (CD31+EMP) in multiple sclerosis. J Neuroinflam 2006; 3: 23-27.
55. Ungvari Z, Wolin MS, Csiszar A. Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? Antiox Redox Signal 2006; 8: 1121-1129.
56. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular response to haemodynamic forces. J Internal Med 2006; 259: 381-392.